JP7203015B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP7203015B2
JP7203015B2 JP2019511574A JP2019511574A JP7203015B2 JP 7203015 B2 JP7203015 B2 JP 7203015B2 JP 2019511574 A JP2019511574 A JP 2019511574A JP 2019511574 A JP2019511574 A JP 2019511574A JP 7203015 B2 JP7203015 B2 JP 7203015B2
Authority
JP
Japan
Prior art keywords
influenza
amino acid
seq
region
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019511574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534242A (ja
JP2019534242A5 (enExample
Inventor
クレイグ トンプソン,
スネトラ グプタ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of JP2019534242A publication Critical patent/JP2019534242A/ja
Publication of JP2019534242A5 publication Critical patent/JP2019534242A5/ja
Priority to JP2022209044A priority Critical patent/JP7762643B2/ja
Application granted granted Critical
Publication of JP7203015B2 publication Critical patent/JP7203015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • A61K39/285Vaccinia virus or variola virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10RNA viruses
    • C07K16/108Orthomyxoviridae (F), e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019511574A 2016-08-25 2017-08-25 免疫原性組成物 Active JP7203015B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022209044A JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1614485.9 2016-08-25
GBGB1614485.9A GB201614485D0 (en) 2016-08-25 2016-08-25 Immunogenic composition
PCT/GB2017/052510 WO2018037246A1 (en) 2016-08-25 2017-08-25 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022209044A Division JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2019534242A JP2019534242A (ja) 2019-11-28
JP2019534242A5 JP2019534242A5 (enExample) 2020-10-01
JP7203015B2 true JP7203015B2 (ja) 2023-01-12

Family

ID=57119951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019511574A Active JP7203015B2 (ja) 2016-08-25 2017-08-25 免疫原性組成物
JP2022209044A Active JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022209044A Active JP7762643B2 (ja) 2016-08-25 2022-12-26 免疫原性組成物

Country Status (8)

Country Link
US (2) US11123422B2 (enExample)
EP (1) EP3504235A1 (enExample)
JP (2) JP7203015B2 (enExample)
CN (1) CN109923125B (enExample)
AU (3) AU2017315238A1 (enExample)
CA (1) CA3034328A1 (enExample)
GB (1) GB201614485D0 (enExample)
WO (1) WO2018037246A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201614485D0 (en) * 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition
US12064478B2 (en) 2018-09-21 2024-08-20 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
GB202204478D0 (en) * 2022-03-29 2022-05-11 Univ Oxford Innovation Ltd Immunogenic compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
CA2035576A1 (en) 1990-02-07 1991-08-08 Alexander R. Neurath Conformational epitopes of human immunodeficiency virus envelope glycoprotein gp120 hiv-1
CZ300688B6 (cs) 1995-09-01 2009-07-15 Corixa Corporation Polypeptid, farmaceutický prostredek a vakcína s jeho obsahem, zpusob prípravy a použití polypeptidu, molekula rekombinantní DNA a její použití, expresní vektor, hostitelská bunka, fúsní porotein a diagnostický kit
EP1490101A4 (en) * 2002-03-05 2006-09-20 Univ Texas PROCESS FOR IMPROVING IMMUNE INDUCTION WITH MDA-7
KR20080052509A (ko) * 2005-04-11 2008-06-11 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시즈, 센터스 포 디지즈 컨트롤 앤드 프리벤션 유행성 독감 바이러스에 대한 백신
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ, エルエルシー インフルエンザウイルスに対する中和抗体
JP2010500034A (ja) * 2006-08-09 2010-01-07 メッドイミューン バクシーンズ,インコーポレイティド インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
KR101745925B1 (ko) 2008-07-18 2017-06-12 메디카고 인코포레이티드 신규 인플루엔자 바이러스 면역화 에피토프
MX340735B (es) 2010-04-09 2016-07-22 Univ Utrecht Holding Bv Proteinas multimericas recombinantes de la influenza.
WO2012021786A2 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US8883171B2 (en) 2010-09-14 2014-11-11 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for influenza
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
WO2013177444A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
JP2016516415A (ja) 2013-03-28 2016-06-09 メディカゴ インコーポレイテッド 植物におけるインフルエンザウイルス様粒子の生成
GB201614485D0 (en) * 2016-08-25 2016-10-12 Univ Oxford Innovation Ltd Immunogenic composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Virology,2012年,Vol. 86, No. 21,p. 11686-11697
Journal of Virology,2014年,Vol. 88, No. 12,p. 6743-6750
Journal of Virology,2014年,Vol. 88, No. 13,p. 7130-7144

Also Published As

Publication number Publication date
GB201614485D0 (en) 2016-10-12
JP2023052092A (ja) 2023-04-11
CA3034328A1 (en) 2018-03-01
JP7762643B2 (ja) 2025-10-30
AU2026200025A1 (en) 2026-01-22
US12390518B2 (en) 2025-08-19
US20190201521A1 (en) 2019-07-04
US20220054625A1 (en) 2022-02-24
WO2018037246A4 (en) 2018-04-19
JP2019534242A (ja) 2019-11-28
US11123422B2 (en) 2021-09-21
CN109923125B (zh) 2024-05-31
EP3504235A1 (en) 2019-07-03
WO2018037246A1 (en) 2018-03-01
AU2017315238A1 (en) 2019-02-21
CN109923125A (zh) 2019-06-21
AU2024227680A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
US12144857B2 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
JP7762643B2 (ja) 免疫原性組成物
US20230165952A1 (en) Betacoronavirus prophylaxis and therapy
US10729758B2 (en) Broadly reactive mosaic peptide for influenza vaccine
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
JP2023522154A (ja) インフルエンザワクチン
JP5730204B2 (ja) インフルエンザm2由来の改変ペプチドワクチン
CN116034115B (zh) 疫苗组合物、方法及其用途
RU2358981C2 (ru) Универсальная вакцина против вируса гриппа птиц
AU2022289009A1 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
EP3713600B1 (en) Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
US20260007734A1 (en) Immunogenic compositions for the prevention of influenza a
CN112955171A (zh) 产生广泛反应、泛表位的免疫原、组合物的方法及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221129

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221226

R150 Certificate of patent or registration of utility model

Ref document number: 7203015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150